![](https://www.diabetesnews.com/wp-content/uploads/2012/11/kidneys-3d-150x150.jpg)
A recent phase 3 clinical trial on the diabetes drug sotagliflozin, an SGLT2 inhibitor, found it had favorable results for people living with severe renal impairment / chronic kidney disease. Read more
A recent phase 3 clinical trial on the diabetes drug sotagliflozin, an SGLT2 inhibitor, found it had favorable results for people living with severe renal impairment / chronic kidney disease. Read more